PharmaLex Group merges with NeoHealthHub

PharmaLex Group, the provider of specialised services for the pharma, biotech and MedTech industries worldwide, has announced a merger with UK pharmaceutical and healthcare services consultancy, NeoHealthHub Limited.

The agreement with NeoHealthHub (NHH), which was signed Thursday, 13 October and closes at the end of October, will be an important step in building a pan-European market access practice covering major markets, including the UK, Germany, Italy, Spain, France and the Nordics.

Founded in 2013, NHH supports its customers by offering innovative and comprehensive market access, data and capability development solutions across all phases of the pharmaceutical and healthcare brand lifecycle through its four business units – NeoNavitas, NeoN, NeoSypher and NeoOptima.

NHH has its headquarters in Lutterworth, Leicestershire, employing around 50 people.

“The merger is a good strategic fit for NHH because we share similar values and corporate culture with PharmaLex, built on an entrepreneurial spirit,” said NHH CEO Simon Doyle.

“Both our organisations support a model of thinking global but acting local, which for us means responding to the unique and complex needs of the pharmaceutical and healthcare marketplace. We have created an organisation and structure that allows us to operate in a truly agile way, maximising opportunities as they emerge. Through the merger, we will be able to build on those opportunities and offer extended services and expertise to our clients, while further expanding the client base.”

“The merger with NHH is a welcome step for both our businesses and we are delighted to welcome the talented and knowledgeable team of market access, data and capabilities experts,” said Pharmalex CEO Dr. Thomas Dobmeyer.

“By combining our expertise, we are better able to support our clients globally with their market access, data and capability needs and at the same time build a very successful local market access business that now includes the UK.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news